This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.86% per year. These returns cover a period from January 1, 1988 through September 7, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
medical: Archive
Can NVO's Semaglutide Push Create Growth Beyond Cardiometabolic Care?
by Ahan Chakraborty
Novo's semaglutide expansion into liver disease and other obesity-related conditions can unlock growth, but competition and clinical risks loom.
NVONegative Net Change LLYNegative Net Change ALTNegative Net Change MDGLNegative Net Change
biotechnology biotechs medical pharmaceuticals
Veeva's DQS Scales Data Automation Across 1,000+ Clinical Studies
by Zacks Equity Research
VEEV's DQS cleans clinical trial data for over 1 million subjects across 1,000+ studies, expanding automation in clinical data management.
VEEVPositive Net Change WSTNegative Net Change GMEDNegative Net Change VCYTPositive Net Change
medical medical-devices
Charles River Gains 75.8% in a Year: What's Driving the Rally?
by Zacks Equity Research
CRL shares have surged 75.8% in a year as RMS trends improve, AI-enabled testing expands and cash flow supports buybacks and investment.
CRLNegative Net Change TFXNegative Net Change GMEDNegative Net Change VCYTPositive Net Change
medical
Reasons to Add Globus Medical Stock to Your Portfolio Now
by Zacks Equity Research
GMED gains musculoskeletal share on strong spine and trauma growth, while product innovation and a debt-free balance sheet support its appeal.
GMEDNegative Net Change TFXNegative Net Change OPKNegative Net Change VCYTPositive Net Change
medical
Is This the Right Time to Add TMO Stock to Your Portfolio?
by Zacks Equity Research
Thermo Fisher's growth gains momentum through innovation, acquisitions and broad end-market strength, but macroeconomic and currency risks remain.
TMONegative Net Change GMEDNegative Net Change PAHCNegative Net Change VCYTPositive Net Change
medical medical-devices
Company News for Oct 7, 2026
by Zacks Equity Research
Companies In The Article Are:AMD,CEG,GOOG,OPCH,MCK and VST
GOOGNegative Net Change AMDNegative Net Change CEGNegative Net Change MCKPositive Net Change VSTNegative Net Change OPCHPositive Net Change
computers medical oil-energy
UnitedHealth Q3 Coming Up: Two Questions Investors Can't Ignore
by Kaibalya Pravo Dey
UNH heads into Q3 with investors focused on whether medical-cost gains can hold as Medicare Advantage margins improve without deeper member losses.
UNHNegative Net Change HUMNegative Net Change ELVNegative Net Change
insurance medical
INSM Stock Slides on CFO Exit, Reiterates '26 Sales View
by Zacks Equity Research
Insmed shares slide after CFO Sara Bonstein's surprise exit, though the company reaffirms 2026 revenue guidance for Brinsupri and Arikayce.
INSMNegative Net Change VKTXNegative Net Change ACIUNegative Net Change
biotechs medical
Centene Narrows Medicare Advantage Footprint as Costs Remain Elevated
by Rajshree Sipani
CNC is narrowing its 2027 Medicare Advantage footprint as elevated costs pressure plan economics, with a sharper focus on dual eligibles.
CNCNegative Net Change UNHNegative Net Change HUMNegative Net Change
insurance medical smart-health
Here's Why You Should Add Merit Medical Stock to Your Portfolio Now
by Zacks Equity Research
MMSI's broad product portfolio, global expansion and strategic M&A support growth, while tariffs and China pressures remain key risks.
MMSIPositive Net Change WSTNegative Net Change OPKNegative Net Change GMEDNegative Net Change
medical medical-devices